In Low v. Pfizer Canada Inc. the British Columbia Court of Appeal accepted Pfizer's argument that the Canadian patent regulatory regime does not provide the basis for a civil action by consumers based on alleged breaches of the patent regime. The Court found, in relation to a claim pertaining to Pfizer's Viagra, that the patent regime conferred no rights on consumers, nor did the regime evince and intention to allow consumers to make claims. The Court accepted that where Parliament has comprehensively legislated in a particular area, as it has in respect to patents, it was reasonable to infer that it did not intend recovery to extend beyond those embodied in the regime.  As a result, Mr. Low's claim, which was based on the patent regime, was dismissed.

The decision arose in the context of a proposed class action brought by an individual consumer alleging that he, and other class members, were entitled to damages based on alleged overcharges for their branded Viagra prescriptions. The proposed class action followed a decision of the Supreme Court of Canada which held that Pfizer had not been entitled to prohibit a generic manufacturer from gaining market entry because the underlying patent had not provided the requisite disclosure required under the Patent Act.   The decision can be found here:  http://canlii.ca/t/gmf7t

While the determination that consumers had no claim was a complete answer to the claims being advanced, the Court of Appeal went on to find that the specific claims for unlawful interference with economic relations and unjust enrichment did not disclose a legal claim. In respect of the tort claim, the Court found that a breach of a statute will only satisfy the "unlawful means" element of intentional interference with economic relations if it is actionable outside the context of the statute.  It was found that Pfizer's conduct was not actionable outside the patent regulatory regime.  Further, having found that the contracts between Pfizer and purchasers of Viagra were valid, a juristic reason existed to deny recovery to the plaintiff and the claim in unjust enrichment was also destined to fail.

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.